Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Gene Therapy. Vancouver Cancer Centre, Vancouver, British Columbia, Canada

Survival: 18.7 months
Toxicity Grade: 3
Treatments: Chemotherapy
Gene Therapy
Country: Canada
City/State/Province: Vancouver, British Columbia
Hospital: Vancouver Cancer Centre
Journal: Link
Date: 12/2001

Patients: This Phase I dose-finding study involved 26 patients with metastatic hormone-refractory prostate cancer. The median age was 69 and the median PSA was 135 (ranged from 30-860). Sites of metastasis included bone and lymph nodes.

Treatment: The treatment consisted of gene therapy Genasense, an antisense Bcl-2 oligonucleotide and chemotherapy mitoxantrone (novantrone). (Genasense or Bcl-2 is thought to be a negative prognostic indicator in prostate cancer and antisense specific to this gene should inhibit its expression.)

Toxicity: Toxicities included neutropenia (grade 3 or 4), thrombocytopenia (grade 2), lymphopenia (grade 3), elevated creatinine (grade 1-2), fever (grade 1-2), and vomiting/diarrhea (grade 2)

Results: Median overall survival was 18.7 months.

Support: The study was supported in part by Genta. Genta markets Genasense.

Correspondence: Kim Chi, MD

E-mail to a Friend Email Physician More Information